Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on OnKure Therapeutics, Inc. (NASDAQ:OKUR) on July 20, 2026.
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on OnKure Therapeutics, Inc. (NASDAQ:OKUR) on July 20, 2026.

HC Wainwright & Co. analysts reiterated a Buy rating on OnKure Therapeutics, Inc. (NASDAQ:OKUR) on July 20, 2026.
OnKure Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $4.12 with a market capitalization of $44.4M. The stock has gained 73.1% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for OnKure Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 9 most recent ratings: 9 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| Mar 16, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 26, 2025 | HC Wainwright & Co. | Buy | N/A |
| Mar 18, 2025 | HC Wainwright & Co. | Buy | N/A |
| Mar 11, 2025 | Oppenheimer | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View OKUR Stock Page
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on OnKure Therapeutics, Inc. (NASDAQ:OKUR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the OKUR forecast page.
Current market data
NASDAQ · OKUR
$3.27
Down: -$0.13 · -4.00%
Live quote updated
Keep reading